Steven Cohen's APLS Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 597,672 shares of Apellis Pharmaceuticals, Inc. (APLS) worth $15.01 M, representing 0.02% of the portfolio. First purchased in 2018-Q4, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in APLS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 1.88 M shares. Largest reduction occurred in Q1 2025, reducing 1.27 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Apellis Pharmaceuticals (APLS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apellis Pharmaceuticals (APLS) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +380,601 | Add 175.33% | 597,672 | $25.12 |
| Q3 2025 | +217,071 | New Buy | 217,071 | $22.63 |
| Q1 2025 | -1.27 M | Sold Out | 0 | $0.00 |
| Q4 2024 | +1.27 M | New Buy | 1.27 M | $31.91 |
| Q2 2024 | -267,823 | Sold Out | 0 | $0.00 |
| Q1 2024 | +267,823 | New Buy | 267,823 | $58.78 |
| Q3 2023 | -1.24 M | Sold Out | 0 | $0.00 |
| Q2 2023 | -640,363 | Reduce 34.07% | 1.24 M | $91.10 |
| Q1 2023 | +1.88 M | New Buy | 1.88 M | $65.96 |
| Q2 2021 | -250,000 | Sold Out | 0 | $0.00 |
| Q1 2021 | +226,600 | Add 968.38% | 250,000 | $42.91 |
| Q4 2020 | -423,536 | Reduce 94.76% | 23,400 | $57.18 |
| Q3 2020 | +238,833 | Add 114.77% | 446,936 | $30.17 |
| Q2 2020 | -112,198 | Reduce 35.03% | 208,103 | $32.66 |
| Q1 2020 | +320,301 | New Buy | 320,301 | $26.79 |
| Q3 2019 | -401,104 | Sold Out | 0 | $0.00 |
| Q2 2019 | +67,475 | Add 20.22% | 401,104 | $25.34 |
| Q1 2019 | +222,613 | Add 200.52% | 333,629 | $19.50 |
| Q4 2018 | +111,016 | New Buy | 111,016 | $13.19 |
Steven Cohen's Apellis Pharmaceuticals Investment FAQs
Steven Cohen first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q4 2018, acquiring 111,016 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Apellis Pharmaceuticals, Inc. (APLS) for 19 quarters since Q4 2018.
Steven Cohen's largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q1 2023, adding 1,879,724 shares worth $123.99 M.
According to the latest 13F filing for Q4 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 597,672 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $15.01 M.
As of the Q4 2025 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 1,879,724 shares, as reported at the end of Q1 2023.